We are a Global
Paediatric Research Network

devoted to determining and implementing the best ways
to prevent, diagnose and treat diseases in children


Linking experts from
around the world

in an independent global collaboration that seeks to standardize
best practices across disease areas and populations


Sharing Values and Goals

such as flexibility, commitment and transparency


Researching the right drug
and the right dose

to generate the scientific data necessary to market drugs
at doses that are safe and effective for children


Understanding the
Immune Response

so as to harness the body's response
to HIV and antiretrovirals


Antimicrobial Resistance

to ensure effective treatments are available
for common infections for generations to come


Paving the way for women,
children and their families

to make powerful informed decisions about their health
and healthcare and improve the quality of their lives


Study reveals moderate effectiveness of Pfizer-BioNTech’s Covid-19 vaccine against Omicron in children aged 5-11

30 June, 2022 - 8:53:57

A large study on the effectiveness of the Pfizer-BioNTech’s Covid-19 vaccine in children aged 5-11 was published in The New England Journal of Medicine. The study was conducted at Israel’s largest healthcare organization, Clalit Health Services, in collaboration with researchers from the University of Padua, Harvard University and University College London. This is one of the…READ MORE

c4c General Assembly

30 June, 2022 - 4:49:43

Between 13th-15th June 2022, around 140 beneficiaries of the c4c consortium met in Ghent Belgium for the c4c General Assembly. This was the first time since 2019 that the consortium has been able to meet altogether in person. The General Assembly was a great opportunity for colleagues to meet again (or for the first time!)…READ MORE

The D3 trial is open and recruiting fast!

30 June, 2022 - 11:11:39

A new trial opened in May, aiming to find out if children and young people living with HIV can take two anti-HIV medicines instead of three. The trial has already recruited 57 participants in Uganda and Thailand. People living with HIV have to take medicines for life. Therefore, it is important to ensure that these…READ MORE

SHIELD trial screens first two patients

28 June, 2022 - 11:09:04

The first two participants of the SHIELD trial (PENTA-22) were screened by Dr. Renate Strehlau and her team at Rahima Moosa Mother and Child Hospital, Johannesburg, South Africa in June 2022.  SHIELD is the first paediatric trial on Fostemsavir, targeting children living with HIV that have developed resistance to two or more antiretroviral drug classes. SHIELD aims…READ MORE


Through independent research into child health operating on global scale, Penta is one of the most prominent scientific organizations dedicated to children’s health.

We are a non-profit Foundation with a remarkable expertise in coordinating projects, optimizing their financial and administrative management, disseminating scientific results and delivering training programs. The Foundation is sponsor of clinical trials according to the GCP guidelines and new relevant European Directives. We have recently entered into a number of framework collaboration agreements with world-leading paediatric research institutions.

We are an operational network, that brings together key stakeholders in paediatric infectious disease, including researchers, clinicians, regulatory bodies, the pharmaceutical industry and patients and their families, to plan and carry out high quality clinical research and training.

The network was established in 1991 as a collaboration between paediatric HIV centres in Europe. The primary aim of the network was to undertake independent clinical trials to address questions about antiretroviral therapies in HIV infected children, where answers could not be extrapolated from trials in adults. In 2011 the Penta network officially evolved into PENTA-ID (Infectious Diseases), extending its research to other paediatric infectious diseases. As such, we have been involved in several non HIV-related projects: where the main research focus is on adults, Penta represents a gateway for paediatric expertise thanks to its very well established network of paediatric hospitals. The Network now spans over 100 clinical sites in 28 countries, providing the access to paediatric patients necessary to perform clinical research.

In addition to coordinating and participating in trials and cohort studies, the Network develops treatment guidelines and training programmes for health care professionals thus contributing to European and global efforts to improve research infrastructure and harmonize and streamline research methods.

Currently the Penta Foundation and its network are involved in research projects in various developing countries that operate along 5 main lines of intervention: HIV and other viruses, Antimicrobials, Paediatric Medicines and Training.

In 2016 a spin off company (Penta ID Innovation) was set up by the Foundation in order to provide services to companies and invest directly in specific projects.

We look forward to building on our existing partnerships and seeking out potential new collaborations. Together, we are continually striving to improve the quality of life of children and their families.

Keep up to date with the latest Penta news

[et_bloom_inline optin_id=”optin_2″]


Map not found, please check "id" parameter in your shortcode.


The Penta ID Network continues to grow, bringing together patients and their care-givers worldwide to address a wide range of healthcare issues.










Founded in 1950, Doctors with Africa CUAMM is now Italy's leading non-governmental organisation working to protect and improve the wellbeing and health of vulnerable communities in Sub-Saharan Africa.
The Global Antibiotic Research & Development Partnership (GARDP) is a not-for-profit R&D organization that addresses global public health needs by developing and delivering new or improved antibiotic treatments, while endeavouring to ensure their sustainable access.
The INSERM-SC10 clinical trials unit was created to enhance the cooperative effort between clinicians and biologists involved in HIV therapeutic trials and to develop this endeavour on a European scale.
The MRC Clinical Trials Unit at UCL is at the forefront of resolving internationally important questions in infections and cancer, and delivering swifter and more effective translation of scientific research into patient benefits.
PHPT overall goal is to help improve HIV prevention and care at the family level through clinical research, focusing primarily on prevention of mother-to-child transmission.

We would like to update you on our recent activities